Evidence map›Paper›PMID 32770124›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2021

MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.

Thomas Denize, Pierre Alexandre Just, Mathilde Sibony, Hélène Blons, Marc Olivier Timsit, Tom Drossart, Deborah Jakubowicz, Chloé Broudin, Aurélien Morini, Thierry Molina and 7 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Article
  3. Review
  4. Article
  5. Contemporary review of papillary renal cell carcinoma-current state and future directions.Virchows Archiv : an international journal of pathology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Thomas DenizeAssistance Publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital Européen Georges Pompidou, Service de Pathologie, F-75015, Paris, France.ORCID http://orcid.org/0000-0002-8618-7691
Pierre Alexandre JustUniversité de Paris, F-75006, Paris, France.
Mathilde SibonyUniversité de Paris, F-75006, Paris, France.
Hélène BlonsAssistance Publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital Européen Georges Pompidou, Département de Biochimie, UF de Pharmacogénétique et Oncologie Moléculaire, F-75015, Paris, France.
Marc Olivier TimsitAssistance Publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital Européen Georges Pompidou, Service d'Urologie, F-75015, Paris, France.
Tom DrossartUniversité de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, F-75015, Paris, France.
Deborah JakubowiczAssistance Publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital Européen Georges Pompidou, Service d'Urologie, F-75015, Paris, France.
Chloé BroudinAssistance Publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital Européen Georges Pompidou, Service de Pathologie, F-75015, Paris, France.
Aurélien MoriniUniversité de Paris, F-75006, Paris, France.
Thierry MolinaUniversité de Paris, F-75006, Paris, France.
Yann VanoUniversité de Paris, F-75006, Paris, France.
Marie Auvray-KuentzUniversité de Paris, F-75006, Paris, France.
Stéphane RichardRéseau national de référence pour cancers rares de l'adulte PREDIR (Maladie de von Hippel-Lindau et prédispositions héréditaires au cancer rénal) labellisée par l'Institut national du cancer, Université Paris Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Arnaud MejeanUniversité de Paris, F-75006, Paris, France.
Anne Paule Gimenez RoqueploUniversité de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, F-75015, Paris, France.ORCID http://orcid.org/0000-0002-4816-670X
Nelly BurnichonUniversité de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, F-75015, Paris, France. nelly.burnichon@inserm.fr.
Virginie VerkarreAssistance Publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital Européen Georges Pompidou, Service de Pathologie, F-75015, Paris, France. virginie.verkarre@aphp.fr.
Université Paris Cité · FRInserm · FRHôpital Necker-Enfants Malades · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biphasic squamoid alveolar papillary renal cell carcinoma (BSA-PRCC) is a recently studied lesion considered a morphologic variant of papillary renal cell carcinoma (RCC), more closely related to type 1. Considering the role of proto-oncogene MET in both sporadic type 1 papillary RCC and hereditary papillary RCC, we aimed to explore the role of MET activation in the oncogenesis of BSA-PRCC. We identified 17 patients with either unique (n = 14) or multiple (n = 3) BSA-PRCC, all localized, and performed an integrative analysis of MET status in 18 formalin-fixed paraffin-embedded tumors combining next-generation sequencing analysis, fluorescent in situ hybridization and immunohistochemistry. Trisomy 7 was found in 86% of tumors (14/16) without MET amplification at 7q31 (15/15). A pathogenic MET genetic variant was identified in 60% (9/15) of cases, at the germline level in 57% (4/7) of tested patients or at the somatic level (5/11). MET expression was observed in all tumors with a higher value of combined score in large cells (mean 97%, range 80-100%) than in small cells (mean 74%, range 10-100%) and was lower in two cases without MET copy number gain. In conclusion, our study provides additional evidence to consider biphasic squamoid alveolar papillary RCC as a morphological variant of type 1 papillary renal RCC. Our data strongly suggest that MET represents a major oncogenic driver gene in BSA-PRCC, harboring a higher frequency of MET mutation that encourages to further explore the benefice of anti-MET targeted therapies for aggressive BSA-PRCC.

Indexed as

MutationAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, PapillaryCarcinoma, Renal CellDNA Copy Number VariationsDNA Mutational AnalysisFemaleGene DosageGenetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryIn Situ Hybridization, FluorescenceBiomarkers, TumorMAS1 protein, humanMET protein, humanProto-Oncogene MasProto-Oncogene Proteins c-met

Identifiers

PMID32770124
OpenAlexW3047743440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.